The 'Holy Grail' in Immuno-Oncology: AC BioScience SA is Aiming to Potentiate Anti-PD-1 Therapy Efficacy through Tumor Cell Conditioning Strategy

Andreas Schläpfer; Christian Auclair; Bassam Janji; Manale Karam; Muhammad Zaeem Noman

doi:10.2533/chimia.2020.771

The 'Holy Grail' in Immuno-Oncology: AC BioScience SA is Aiming to Potentiate Anti-PD-1 Therapy Efficacy through Tumor Cell Conditioning Strategy

Authors

Andreas Schläpfer AC Bioscience, EPFL Innovation Park, CH-1024 Ecublens, Switzerland;, Email: andreas.schlaepfer@ac-bioscience.com
Christian Auclair AC Bioscience, EPFL Innovation Park, CH-1024 Ecublens, Switzerland
Bassam Janji Department of Oncology, Luxembourg Institute of Health, Luxembourg, L-1526 Luxembourg City, Luxembourg
Manale Karam AC Bioscience, EPFL Innovation Park, CH-1024 Ecublens, Switzerland
Muhammad Zaeem Noman Department of Oncology, Luxembourg Institute of Health, Luxembourg, L-1526 Luxembourg City, Luxembourg

DOI:

https://doi.org/10.2533/chimia.2020.771

PMID:

33115558

Keywords:

Ac bioscience sa, Acb1801, Cancer therapies, Immune checkpoint inhibitors, Swiss biotech

Abstract

AC BioScience is a Swiss biotech company based at the EPFL Innovation Park and Biopôle, dedicated to developing groundbreaking therapies to fight a range of cancers and infectious diseases. We are about to start clinical trials with two of four leading-edge cancer drugs mainly focusing on immune-oncology and tumor vascular normalization with multi-billion $ sales potential. Here, we present our strategy and one of our pioneering drug candidates that has already shown exceptional results with tumor cell conditioning to improve the efficacy of immune checkpoint inhibitors.